Invest1 publisher2 min readPublished
Tempus AI's 31.91% week supplied nine points of a Korean ETF's 19.56% return
Hana Asset Management's medical AI fund led every ETF listed in South Korea last week, helped by a Morgan Stanley estimate that Medicare coverage could add $330m to $400m of annual revenue at its largest holding.
The Investor · Invest desk
What happened
- Hana Asset Management's 1Q U.S. Medical AI ETF returned 19.56% over the past week, the best of any ETF listed in South Korea, according to ETF CHECK data cited on the 20th.
- The fund, listed in July last year, invests in 15 U.S.-listed medical AI companies, including Recursion Pharmaceuticals, Intellia Therapeutics and Intuitive Surgical alongside Tempus AI.
- Moderna shares surged 176.97% in a single day last month on positive Phase 3 results, after which buying spread to firms working on AI-driven precision diagnostics, drug discovery and genetic analysis.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- constraint At 28.24% in one name, the fund cannot diversify away a Tempus repricing; the other 14 holdings would each need outsized moves in the opposite direction to offset it.
- exposure Holders of a won-listed sector fund are carrying the outcome of a U.S. Medicare coverage determination on two specific Tempus tests, priced today off a broker's revenue estimate.
- contradiction Moderna's 176.97% single-day move came from trial data, so the same week's sector bid had a clinical trigger as well as a reimbursement one, and the two readings point to different next catalysts.
- precedent A founder's conference outlook plus a sell-side revenue range was enough for a 31.91% week, so the sector's next repricing can arrive on commentary and an estimate alone.
Tempus AI at 28.24% of the book, rising 31.91%, added 9.01 percentage points to Hana Asset Management's 1Q U.S. Medical AI ETF, which returned 19.56% for the week [3][4][1][1]. One holding produced 46% of the fund's return [2]. The other 10.55 points came off the remaining 71.76% of the portfolio, an average gain of roughly 14.7% across the other 14 names [3].
Fourteen holdings averaging 14.7% is a sector bid, and the week's sector catalyst was clinical. Moderna said on the 19th of last month that a Phase 3 trial of intismeran autogene, the personalized mRNA cancer vaccine it developed with Merck, had produced positive results [7]. Its shares surged 176.97% in a single day, and buying then spread to companies working on AI-driven precision diagnostics, drug discovery and genetic analysis [8].
Tempus's own leg is more specific. The stock extended its advance after founder and chief executive Eric Lefkofsky laid out a growth outlook at the Morgan Stanley Global Healthcare Conference on the 15th [5]. Morgan Stanley attached a figure to Medicare reimbursement coverage: an additional $330m to $400m of annual revenue from the xT tissue-based cancer test and the xF liquid biopsy [6]. The midpoint is $365m [4]. The report describes that as what coverage could generate and does not state Tempus's revenue or market value, so the range cannot be set against either [12].
"Since last year, we have viewed healthcare as the industry where AI will have the greatest impact," said Kim Seung-hyun, head of the ETF and quant solutions division at Hana Asset Management [9]. "More recently, AI technology has spread across the healthcare industry, including precision diagnostics, drug discovery and genetic analysis, and the growth potential of these companies is coming into focus in earnest," he said [10].
A buyer of the fund takes on that concentration. Equal weighting across 15 names would put 6.67% in each, so Tempus at 28.24% carries 4.2 times a neutral position [5]. A 10% fall in Tempus alone removes 2.82 points from the fund before any other holding moves [6]. I would expect the next large weekly print, in either direction, to come from the same name. If it comes instead from the other 14 while Tempus sits flat, the fund is tracking healthcare sentiment and the single-name reading is wrong.
Tempus was already described as the sector's bellwether, and the source attributes its move to raised revenue forecasts and expectations of revenue growth [11]. That is an earnings story. A coverage decision would confirm or cut it.
What to watch
- A Medicare coverage determination on xT or xF, and whether the revenue it supports falls inside Morgan Stanley's $330m to $400m range.
- Whether Hana Asset Management trims the 28.24% Tempus weighting at rebalance or lets it drift higher.
- Whether the fund's next big weekly print comes from Tempus again or from the other 14 holdings.